Join
Live feed
·
PRReleasevia Quantisnow
Apexigen Inc. logo

Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma

ByQuantisnow·Wall Street's wire, on your screen.
APGN· Apexigen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APGN (Apexigen Inc.) and more on Quantisnow.